Published in Vaccine on September 09, 2010
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis (2011) 0.95
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS (2015) 0.90
Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs. Drug Alcohol Rev (2012) 0.79
Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine (2014) 0.78
Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment. Contemp Clin Trials (2014) 0.76
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep (2001) 5.34
Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 4.58
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 4.21
Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol (2002) 4.20
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol (1993) 2.61
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr (2004) 2.39
Prospects for a vaccine against the hepatitis C virus. Nature (2005) 2.38
HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr (2006) 2.35
Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology (2010) 2.30
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
Hepatitis C virus reinfection in injection drug users. Hepatology (2006) 2.25
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis (2007) 2.02
A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend (2003) 1.99
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (2006) 1.87
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology (2002) 1.83
Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis (2000) 1.75
An HIV vaccine--challenges and prospects. N Engl J Med (2008) 1.69
High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health (2007) 1.67
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology (2006) 1.65
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology (2008) 1.55
Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis (2000) 1.54
Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med (2008) 1.53
Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: does it work? Vaccine (2009) 1.52
HIV vaccine acceptability: a systematic review and meta-analysis. AIDS (2010) 1.51
HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine (2005) 1.50
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology (2000) 1.49
Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health (2005) 1.42
Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis (2005) 1.35
Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis (2001) 1.33
HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care (2007) 1.31
Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS (2007) 1.31
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. AIDS Rev (2003) 1.28
Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health (2001) 1.26
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat (2007) 1.23
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS (2004) 1.18
Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics (2006) 1.15
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin (2009) 1.10
Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend (2007) 1.08
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics (2009) 1.07
Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health (2002) 1.06
Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend (2007) 1.05
Hepatitis C vaccine: supply and demand. Lancet Infect Dis (2008) 1.04
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr (2009) 1.04
Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS (2004) 1.03
Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine (1997) 1.03
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol (2010) 1.02
The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess (2006) 1.00
Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol (2001) 0.99
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine (2009) 0.97
Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med (2004) 0.96
Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine (2005) 0.95
The war on drugs: a devastating public-policy disaster. Lancet (2009) 0.94
Impact of biomedical research on African Americans. J Natl Med Assoc (2001) 0.93
Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl (2003) 0.90
Supervised injecting facilities: time for scale-up? Lancet (2008) 0.90
Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol (2005) 0.90
Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity? Hepatology (2007) 0.88
Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs. Int J Drug Policy (2009) 0.87
Prospects for an AIDS vaccine. Clin Med (2003) 0.85
Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users. Vaccine (2009) 0.84
Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine (2010) 0.82
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy (2007) 0.80
"Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine (2010) 0.80
Vaccine-induced T-cell responses against HCV: one step taken, more to follow. Gastroenterology (2007) 0.80
Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemp Clin Trials (2009) 0.79
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med (2007) 4.14
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr (2003) 2.37
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol (2009) 2.31
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction (2005) 2.24
Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies. Subst Use Misuse (2006) 2.22
A review of barriers and facilitators of HIV treatment among injection drug users. AIDS (2008) 2.21
A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood) (2013) 2.09
Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place (2009) 2.07
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS (2009) 2.07
Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ (2006) 2.06
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Income generating activities of people who inject drugs. Drug Alcohol Depend (2007) 1.95
Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. Int J Drug Policy (2007) 1.90
Public injection settings in Vancouver: physical environment, social context and risk. Int J Drug Policy (2007) 1.86
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med (2006) 1.83
Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy (2008) 1.83
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction (2007) 1.81
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J (2004) 1.77
Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth. Drug Alcohol Rev (2008) 1.77
Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis (2011) 1.74
Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS (2006) 1.72
Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia. Am J Public Health (2008) 1.71
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend (2005) 1.69
Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users. Int J Epidemiol (2004) 1.67
Associations between childhood maltreatment and sex work in a cohort of drug-using youth. Soc Sci Med (2007) 1.66
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health (2003) 1.66
Illicit drug addiction, infectious disease spread, and the need for an evidence-based response. Lancet Infect Dis (2008) 1.66
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting. Drug Alcohol Depend (2006) 1.64
Staging for antiretroviral therapy among HIV-infected drug users. JAMA (2004) 1.64
Factors associated with early adolescent initiation into injection drug use: implications for intervention programs. J Adolesc Health (2006) 1.64
Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol (2012) 1.63
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse (2010) 1.61
Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J (2007) 1.60
Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend (2007) 1.60
Drug treatment courts in Canada: an evidence-based review. HIV AIDS Policy Law Rev (2007) 1.59
Unravelling the impact of ethnicity on health in Europe: the HELIUS study. BMC Public Health (2013) 1.59
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis (2014) 1.59
Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users. Health Place (2006) 1.58
Elevated overdose mortality rates among First Nations individuals in a Canadian setting: a population-based analysis. Addiction (2010) 1.57
Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev (2008) 1.57
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology (2008) 1.55
The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr (2003) 1.54
Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep (2005) 1.53
Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med (2007) 1.53
Effect of drug law enforcement on drug market violence: a systematic review. Int J Drug Policy (2011) 1.52
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Do supervised injecting facilities attract higher-risk injection drug users? Am J Prev Med (2005) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS (2013) 1.51
Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis (2014) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies. J Public Health (Oxf) (2008) 1.49
Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr (2005) 1.48
Physical violence among a prospective cohort of injection drug users: a gender-focused approach. Drug Alcohol Depend (2008) 1.46
Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J (2005) 1.45